Cowen analyst Phil Nadeau is out with a research note on shares of Dynavax (NASDAQ:DVAX) following updates presented at the American Society of Clinical Oncology (ASCO) …
Cowen’s Phil Nadeau sings the praises of this “undervalued” biotech stock, encouraged to see DVAX’s cancer drug SD-101 revealed well tolerated results in a mid-stage trial.
J.P.
Brian Abrahams believes there could be between 20% to 30% in upside potential waiting in the wings for DVAX shares.
Dynavax Technologies Corporation (NASDAQ:DVAX) announced that HEPLISAV-B™ (Hepatitis B Vaccine) for the prevention of hepatitis B in adults is now available for prescription in the …
Cowen believes Dynavax has an asset on its hands that fulfills a valuable unmet need.
Dynavax Technologies Corporation (NASDAQ:DVAX) has won U.S.
Dynavax Technologies Corporation (NASDAQ:DVAX) announced initiation of dosing in patients with non-small cell lung cancer (NSCLC). This multi-center, open label trial is designed …
Analyst initiates a bullish perspective on Dynavax, ascribing a probability of 95% approval for its lead asset.
Kamada: Jefferies Sees 60% Upside for the Stock Kamada Ltd (NASDAQ:KMDA) has an upcoming PDUFA date on August 29, 2017 for its anti-rabies IgG …
